Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea

Soo Young Hwang; Ju Dong Yang

doi:10.17998/jlc.2024.12.04

Articles

Page Path: HOME > J Liver Cancer > Volume 25(1); 2025 > Article

Editorial Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea: Soo Young Hwang¹, Ju Dong Yang²; Journal of Liver Cancer 2025;25(1):4-6.
DOI: https://doi.org/10.17998/jlc.2024.12.04
Published online: December 5, 2024

¹Department of Internal Medicine, University of Maryland Medical Center, Midtown Campus, Baltimore, Maryland, USA

²Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA

Corresponding author: Ju Dong Yang, Cedars-Sinai Medical Center, Health Sciences Associate Clinical Professor, University of California, Los Angeles, 8900 Beverly Boulevard, Los Angeles, CA 90048, USA E-mail: judong.yang@cshs.org

• Received: November 30, 2024 • Accepted: December 4, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1,189 Views
51 Downloads
1 Citation

prev next

Full Article

Download PDF

Article information
References

Over the past two decades, the management of hepatocellular carcinoma (HCC) has evolved significantly. Multidisciplinary and personalized approach to patient care, improvement in techniques of various locoregional treatments, and most notably, progress occurring in systemic therapies for advanced unresectable HCC have improved prognosis. Since sorafenib was approved in 2008¹as the first systemic treatment for advanced HCC, tyrosine kinase inhibitors and immune checkpoint inhibitors with or without anti-vascular endothelial growth factor (anti-VEGF) inhibitors have been rapidly emerging, including lenvatinib,²atezolizumab plus bevacizumab,³durvalumab plus tremelimumab,⁴and most recently nivolumab plus ipilimumab as first-line treatment.⁵Minimally invasive surgery (i.e., robotic and laparoscopic surgery) is increasing based on promising results in overall survival and fewer complications compared to open surgery,^6,⁷and local ablative techniques have diversified, such as radiofrequency, microwave ablation, cryoablation, and injection of chemicals.⁸Transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and stereotactic body radiation therapy (SBRT) are developing into a more targeted and individualized approach such as the drug-eluting beads TACE⁹or the personalized dosimetry approach in TARE.¹⁰The combination of different locoregional and systemic treatment modalities such as TACE in combination of sorafenib and immune checkpoint inhibitors or TACE plus SBRT has been shown to improve survival outcomes and is increasingly being explored in recent studies.^11,¹²

In this issue of the Journal of Liver Cancer, Han et al.¹³analyzed the trends in epidemiology, etiology, and treatment patterns for HCC in South Korea between 2008 and 2022 using the National Health Insurance database. Overall, there was a decreasing trend in incidence, with the crude rate declining from 23.9 cases in 2008 to 20.4 cases per 100,000 by 2022. However, there was a notable increase in the proportion of elderly (above the age of 70). There was a shift in the etiology of HCC: portion of hepatitis B virus decreased (68.9% of HCC cases in 2008 and 59.7% in 2022) while an increase in metabolic dysfunction associated fatty liver disease (MAFLD) (7.5% in 2008 to 11.8% in 2022) and alcohol-associated liver disease (ALD) (8.9% in 2008 to 15.8% in 2022) were observed. Transarterial therapy was the dominant treatment in 2008, accounting for 49.9% of initial treatments, but decreased to 36.6% in 2022. Surgical resection increased from 12.2% to 21.3%, with a surge in laparoscopic resections, and systemic therapy increased from 0.2% to 9.6% between 2008 and 2022. Sorafenib was the sole systemic therapy of choice earlier, while atezolizumab-bevacizumab became the most widely used in 2022 taking up to 63.1% of patients receiving systemic therapy. Best supportive care also decreased from 31.7% to 21.3%.

Along with the rising prevalence of metabolic syndrome, MASLD is the most rapidly increasing etiology of HCC cases globally, increasing by 39% from 2010 to 2019, and the fastest-growing cause of liver cancer deaths, with a 38% increase, compared to a 21% rise in other causes.¹⁴The rise in global per-capita alcohol consumption has also led to an increase in ALD and alcohol-associated HCC globally, especially during the COVID-19 pandemic.¹⁵South Korea, located in East Asia, is an endemic area to hepatitis B,¹⁶and demonstrated a decrease in hepatitis B virus (HBV)-associated HCC cases from 68.9% to 59.7% between 2008 and 2022, in contrast to the increasing proportion of HCC due to MASLD and ALD. The use of oral antiviral treatment for HBV, such as tenofovir, and the expansion of universal vaccination, especially in newborns and infants, have contributed to a marked decline in prevalence in South Korea and East Asia.¹⁷

The proportion of best supportive care as initial treatment has decreased while the proportion of curative treatment for HCC has increased, likely due to improvements in early detection and more widespread surveillance. Additional measures need to be implemented to improve adherence and compliance to surveillance and in enhanced screening methods, such as more advanced imaging techniques (e.g., abbreviated magnetic resonance imaging)¹⁸or the use of non-invasive biomarkers (e.g., alpha-fetoprotein [AFP]-L3, des-gamma-carboxy prothrombin [DCP]), which will identify HCC at earlier stages when curative treatments are feasible.¹⁹

The shift of systemic therapies from the dominance of sorafenib to the emergence of atezolizumab-bevacizumab or lenvatinib presented in this study reflects the significant progress in systemic treatment of HCC management, offering promising survival benefits for patients with advanced-stage disease, although data is limited for non-reimbursed treatments in South Korea. An additional limitation is that it lacks data on the long-term prognostic impact of the change in etiology and treatment pattern on a national basis. While we expect to see improvement in survival outcomes with improvement in therapeutic modalities, it is essential to validate the efficacy of these newly emerging systemic therapies through a large-scale cohort and guide treatment directions in the future.

This study highlighted a shift in patient demographics with an increase in the older patient population, changes in etiology with ALD and MASLD emerging as major etiologies, increased utilization of minimally invasive surgeries, and the emergence and development of systemic treatments increasing adoption of immune checkpoint inhibitor treatment for advanced HCC that align with the global trends of HCC epidemiology. Future studies should investigate how the shifting landscape of HCC etiology and treatment strategies influence patient outcomes and prognosis.

Article information

Conflicts of Interest

Ju Dong Yang provides a consulting service for AstraZeneca, Eisai, Exact Sciences, Exelixis, Fujifilm Medical Sciences. Ju Dong Yang is an editorial board member of Journal of Liver Cancer and was not involved in the review process of this article. Otherwise, the authors have no conflicts of interest to disclose.

Ethics Statement

Not applicable.

Funding Statement

This research is supported by NCI K08CA259534.

Data Availability

Not applicable.

Author Contributions

Conceptualization: JDY

Supervision: JDY

Writing - original draft: SYH

Writing - review & editing: SYH, JDY

References

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378−390.Article PubMed
2. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163−1173.Article PubMed
3. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894−1905.Article PubMed
4. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1:EVIDoa2100070. PubMed
5. Galle PR, Decaens T, Kudo M, Qin S, Fonseca L, Sangro B, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW. J Clin Oncol 2024;42 Suppl 17:LBA4008. Article
6. Di Benedetto F, Magistri P, Di Sandro S, Sposito C, Oberkofler C, Brandon E, et al. Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma. JAMA Surg 2023;158:46−54.PubMed
7. Kato Y, Sugioka A, Kojima M, Mii S, Uchida Y, Iwama H, et al. Minimally invasive anatomic liver resection for hepatocellular carcinoma using the extrahepatic Glissonian approach: surgical techniques and comparison of outcomes with the open approach and between the laparoscopic and robotic approaches. Cancers (Basel) 2023;15:2219. Article PubMed PMC
8. Han S, Sung PS, Park SY, Kim JW, Hong HP, Yoon JH, et al. Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association. J Liver Cancer 2024;24:131−144.Article PubMed PMC PDF
9. Wang CY, Xia JG, Yang ZQ, Zhou WZ, Chen WH, Qi CJ, et al. Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma. Sci Rep 2020;10:4434. Article PubMed PMC PDF
10. Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, et al. Longterm overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med 2024;65:264−269.Article PubMed PMC
11. Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, et al. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: a propensity score matched analysis. Surg Oncol 2019;28:228−235.Article PubMed
12. Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, et al. Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a retrospective study. Front Mol Biosci 2021;7:609322. Article PubMed PMC
13. Han JW, Sohn W, Choi GH, Jang JW, Seo GH, Kim BH, et al. Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study. J Liver Cancer 2024;24:274−285.Article PubMed PMC PDF
14. Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab 2022;34:969−977.e2.Article PubMed PMC
15. Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol 2023;20:37−49.Article PubMed PMC PDF
16. Yoon JH, Cho SH, Kim DY, Yu SJ, Han KH. Epidemiological and clinical history of viral hepatitis in Korea. Infect Chemother 2021;53:159−165.Article PubMed PMC PDF
17. GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol 2022;7:796−829.PubMed PMC
18. Khatri G, Pedrosa I, Ananthakrishnan L, de Leon AD, Fetzer DT, Leyendecker J, et al. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. J Magn Reson Imaging 2020;51:415−425.Article PubMed PDF
19. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020;72:250−261.Article PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

Correspondence to editorial on “Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea”
Ji Won Han, Bo Hyun Kim
Journal of Liver Cancer.2025; 25(1): 7. CrossRef

ePub Link

Download Citation

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea

J Liver Cancer. 2025;25(1):4-6. Published online December 5, 2024

DOI: https://doi.org/10.17998/jlc.2024.12.04

XML Download

Related articles

Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea